{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreieiswintdahhaubcwe6rwrxm4gu3hfuc37mshxefb4dq6tsujuxwu",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmrluuqsoux2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieffhxgxyuvfkzzjwrfiq3k2y4xzjxsd3xzdlt4d6b66heaqzygim"
    },
    "mimeType": "image/jpeg",
    "size": 80705
  },
  "path": "/news/2026-05-residual-liver-cancer-persist-hepatitis.html",
  "publishedAt": "2026-05-26T13:00:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "National Taiwan University Hospital (NTUH), in collaboration with multiple medical centers across Taiwan, has found that patients with hepatitis C remain at a significantly elevated risk of hepatocellular carcinoma (HCC) even after successful viral eradication with direct-acting antivirals (DAAs), particularly if metabolic dysfunction-associated steatotic liver disease (MASLD) is present.",
  "title": "Residual risks of liver cancer persist after hepatitis C cure, finds study"
}